Postepy w kardiologii interwencyjnej = Advances in interventional cardiology最新文献

{"title":"Idarucizumab for dabigatran reversal in cardiac tamponade complicating percutaneous intervention in ST elevation myocardial infarction.","authors":"Marta Kurdziel,&nbsp;Bartosz Hudzik,&nbsp;Anna Kazik,&nbsp;Jacek Piegza,&nbsp;Janusz Szkodziński,&nbsp;Mariusz Gąsior","doi":"10.5114/aic.2021.104784","DOIUrl":"https://doi.org/10.5114/aic.2021.104784","url":null,"abstract":"<p><p>An 83-year-old man with a history of permanent atrial fibrillation (AF) anticoagulated by dabigatran 150 b.i.d., type 2 diabetes mellitus, and hypertension was admitted to the hospital with a diagnosis of ST-elevation myocardial infarction (STEMI). The patient was loaded with 300 mg of aspirin <i>p.o.</i>, 5000 IU of unfractionated heparin <i>i.v.</i> and 600 mg of clopidogrel and was transferred to the catheterization laboratory. Coronary angiography demonstrated left anterior descending artery (LAD) occlusion. During the LAD angioplasty a dissection of a distal part of the LAD and the blood extravasation to the pericardium occurred (Figure 1 A). Idarucizumab 2 × 2.5 g <i>i.v.</i> was administered and the inflated balloon maintained at the site of coronary perforation. About 10 min after the end of idarucizumab infusion, the balloon was deflated and the patient presented with clinical symptoms of cardiac tamponade such as blood pressure decrease and tachycardia. The echocardiographic assessment revealed up to 16 mm accumulation of pericardial fluid (Figure 2 A). Immediately the covered stent was implanted (Papyrus, Biotronik) and the pericardiocentesis was carried out. 320 ml of blood was finally drained. Control contrast injection revealed a covered perforating zone with no contrast extravasation (Figure 1 B). The echocardiographic control revealed pericardial effusion less than 5 mm (Figure 2 B). The patient was stable with a blood pressure of 130/80 mm Hg, a heart rate of 100-130/min (AF), and without chest pain. No significant reduction in the red blood cell count was observed. Antiplatelet therapy was given consisting of aspirin and clopidogrel. In the following days enoxaparin was introduced and finally changed to dabigatran 110 mg b.i.d.</p>","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"129-130"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8c/f4/PWKI-17-43653.PMC8039931.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38885397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small buddy balloon catheter technique facilitates deliverability of other balloons or stents in challenging cases.","authors":"Sylwia Iwanczyk,&nbsp;Wojciech J Skorupski,&nbsp;Stefan Grajek,&nbsp;Marta Kałużna-Oleksy,&nbsp;Michał B Lesiak,&nbsp;Maciej Lesiak,&nbsp;Marek Grygier","doi":"10.5114/aic.2021.104775","DOIUrl":"https://doi.org/10.5114/aic.2021.104775","url":null,"abstract":"Introduction Despite improvements in balloon and stent technology, percutaneous coronary intervention (PCI) in calcified, tortuous, angulated or previously stented vessels is still a therapeutic challenge. The proper preparation of the vessel, confirmed by the smooth passage of smaller balloon catheters, often remains insufficient to deliver a larger, stiffer balloon or stent catheter in place of the target lesion. We describe a modified buddy balloon catheter technique that facilitates the deliverability of larger balloons or stents to these challenging lesions when the routinely used buddy wire technique as the first step fails. The small buddy balloon catheter technique is a simple extension of the buddy wire technique in which a small monorail uninflated balloon, of up to 1.5 mm, is positioned on the buddy wire distally or at the point where the balloon/stent becomes stuck. The small buddy balloon catheter appears to reduce the resistance of the rough surface, especially the angulated segment of the vessel, and facilitates other balloon or stent catheter passage. This does not concern a balloon inflation but rather catheter shaft properties. Since that technique is used in our high-volume catheterization laboratory with a surprisingly high success rate we think that it is worth sharing our experience with other operators. Consequently, we have decided to present these 2 cases.","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"101-104"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/45/PWKI-17-43644.PMC8039919.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38885946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the results of transcatheter aortic valve implantation in patients with bicuspid and tricuspid aortic valve.","authors":"Piotr A Chodór,&nbsp;Krzysztof Wilczek,&nbsp;Karolina Chodór-Rozwadowska,&nbsp;Roman Przybylski,&nbsp;Jan Głowacki,&nbsp;Tomasz Niklewski,&nbsp;Łukasz Włoch,&nbsp;Mariusz Gąsior,&nbsp;Marian Zembala,&nbsp;Zbigniew Kalarus","doi":"10.5114/aic.2021.104773","DOIUrl":"https://doi.org/10.5114/aic.2021.104773","url":null,"abstract":"<p><strong>Introduction: </strong>Indications for transcatheter aortic valve implantation (TAVI) are constantly expanding, including younger patients. Bicuspid aortic valves (BAV) often occur in this group. In order to achieve optimal treatment results in younger patients, it is necessary to develop an effective method for selecting the size of implanted valves.</p><p><strong>Aim: </strong>To compare the results of TAVI with use of a self-expanding prosthesis in patients with a BAV and a tricuspid aortic valve (TAV) with valve selection based on annular sizing.</p><p><strong>Material and methods: </strong>The diagnosis of BAV and TAV and measurements (annular sizing) were based on multi-slice computed tomography scans. Eighty-three patients received a self-expanding CoreValve or Evolut R prosthesis. In group I (BAV) there were 21 (25.3%) patients and in group II (TAV) there were 62 (74.7%) patients.</p><p><strong>Results: </strong>The groups did not differ in terms of baseline clinical characteristics. Device success was achieved in 16 (76.2%) and 55 (88.7%) (<i>p</i> = NS) in group I and II respectively. Composite endpoints: early safety occurred in 5 (23.8%) and 11 (17.7%) patients (<i>p</i> =NS) in group I and II respectively; clinical efficacy occurred in 10 (47.6%) and 28 (45.2%) patients (<i>p</i> = NS) in group I and II respectively. 30-day mortality was 4.8% vs 9.7%, 1-year mortality was 28.6% vs 17.7% (<i>p</i> = NS) in group I and II respectively.</p><p><strong>Conclusions: </strong>TAVI in patients with severe aortic stenosis and BAV is as effective as in patients with TAV using self-expanding prostheses if the valve selection is based on annular sizing.</p>","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"82-92"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/cb/PWKI-17-43642.PMC8039923.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38885944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-day experience of pulmonary embolism response team (PERT) during the COVID-19 pandemic: three urgent percutaneous pulmonary embolectomies in acute pulmonary embolism.","authors":"Andrzej Łabyk,&nbsp;Michał Potępa,&nbsp;Mateusz Jermakow,&nbsp;Michał Machowski,&nbsp;Piotr Pruszczyk,&nbsp;Marek Roik","doi":"10.5114/aic.2021.104777","DOIUrl":"https://doi.org/10.5114/aic.2021.104777","url":null,"abstract":"Percutaneous pulmonary embolectomy (PPE) is a rapidly evolving therapy in selected acute pulmonary embolism (APE) patients [1–5] Novel percutaneous procedures tend not to be common, even in reference centers","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"109-111"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/30/PWKI-17-43646.PMC8039916.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38885948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twelve-month outcomes of transapical transcatheter aortic valve implantation in patients with severe aortic valve stenosis.","authors":"Łukasz Wiewiórka,&nbsp;Robert Sobczyński,&nbsp;Jarosław Trębacz,&nbsp;Jerzy Sadowski,&nbsp;Dariusz Dudek,&nbsp;Maciej Stąpór,&nbsp;Janusz Konstanty-Kalandyk,&nbsp;Robert Musiał,&nbsp;Andrzej Gackowski,&nbsp;Krzystof Malinowski,&nbsp;Paweł Kleczyński,&nbsp;Krzysztof Żmudka,&nbsp;Bogusław Kapelak,&nbsp;Jacek Legutko","doi":"10.5114/aic.2021.104771","DOIUrl":"https://doi.org/10.5114/aic.2021.104771","url":null,"abstract":"<p><strong>Introduction: </strong>Transapical access (TA) transcatheter aortic valve implantation (TAVI) (TA-TAVI) represents one of the possible routes in patients with severe aortic stenosis (AS) who are not suitable for transfemoral access.</p><p><strong>Aim: </strong>To assess early- and mid-term clinical outcomes after TA-TAVI.</p><p><strong>Material and methods: </strong>Patients with severe symptomatic AS undergoing TA-TAVI from November 2008 to December 2019 were enrolled. Clinical and procedural characteristics as well as clinical outcomes including all-cause mortality during 12-month follow-up were assessed.</p><p><strong>Results: </strong>Sixty-one consecutive patients underwent TA-TAVI for native AS. Patients were elderly with median age of 80.0 (76.0-84.0) years; 55.7% were males. Median baseline EuroSCORE I and STS scores were 18.2% (11.6-27.7) and 4.8% (3.3-8.2), respectively. The procedural success rate was 96.7%. In-hospital, 30-day and 12-month mortality rates were 9.8%; 18.0% and 24.6%, respectively. The main periprocedural and in-hospital complications were bleeding complications (14.8%). The following factors were associated with 12-month mortality: previous cerebrovascular event (CVE), glomerular filtration rate (GFR), aortic valve area (AVA), right ventricular systolic pressure (RVSP) and serum level of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) (RR for CVE 3.17, 95% confidence interval (CI): 1.15-8.76: <i>p</i> = 0.026; RR for AVA per 0.1 cm² 1.28, 95% CI: 1.03-1.55: <i>p</i> = 0.024; RR for GFR per 1 ml/min 0.96: 95% CI: 0.94-0.99: <i>p</i> = 0.007; RR for NT-proBNP per 1000 pg/ml 1.07: 95% CI: 1.01-1.17: <i>p</i> = 0.033; RR for RVSP per 1 mm Hg 1.07: 95% CI 1.02-1.16: <i>p</i> = 0.011).</p><p><strong>Conclusions: </strong>Transapical TAVI in high-risk patients provides good hemodynamic results with acceptable outcomes.</p>","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"68-74"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/24/PWKI-17-43640.PMC8039915.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38885942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morphological applicability of currently available stent grafts in the endovascular repair of asymptomatic abdominal aortic aneurysm in East-Central European patients.","authors":"Jolanta Tomczak,&nbsp;Łukasz Dzieciuchowicz","doi":"10.5114/aic.2021.104774","DOIUrl":"https://doi.org/10.5114/aic.2021.104774","url":null,"abstract":"<p><strong>Introduction: </strong>Currently, there is a wide range of commercially available devices for endovascular aneurysm repair (EVAR) that differ in terms of both anatomical requirements and the technology and technique of deployment.</p><p><strong>Aim: </strong>To assess the applicability of currently commercially available devices for EVAR in the treatment of an asymptomatic abdominal aneurysm (AAA).</p><p><strong>Material and methods: </strong>The study group included 100 patients with infrarenal AAA with a maximum diameter ≥ 50 mm, qualified for invasive treatment at the University Hospital in 2013-2014. The aortoiliac morphological characteristics of the AAA were evaluated on preoperative computed tomography angiograms using the OsiriX DICOM viewer in the 3D-MPR mode. The morphological applicability of 14 types of CE-marked and FDA-approved stent grafts was determined based on their instructions for use (IFU).</p><p><strong>Results: </strong>EVAR was feasible with at least one of the analysed devices in 68% of patients. The morphological applicability was as follows: Excluder Conformable (65%), Ovation iX (51%), Endurant II (47%), Treo (45%), Excluder C3 (45%), AFX 2 (45%), Incraft (44%), E-tegra (44%), Zenith Alfa (41%), Zenith Flex (40%), Anaconda (39%) Aorfix (37%), Altura (34%), and E-vita (20%). The differences in the stent graft applicability were statistically significant (<i>p</i> < 0.001). A wide diameter of the common iliac artery, angulated proximal neck, and diameter of proximal neck out of range constituted the most frequent causes of EVAR inapplicability.</p><p><strong>Conclusions: </strong>The IFU-based applicability of currently available AAA stent graft systems differs significantly. Despite the constant evolution of EVAR technology, at least 32% of AAA will require a different therapeutic approach.</p>","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"93-100"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/4e/PWKI-17-43643.PMC8039927.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38885945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A patient with an hourglass shaped fractured coronary stent.","authors":"Andreas Y Andreou,&nbsp;Angelos Tyrlis","doi":"10.5114/aic.2021.104780","DOIUrl":"https://doi.org/10.5114/aic.2021.104780","url":null,"abstract":"","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"116-121"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/0d/PWKI-17-43649.PMC8039929.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38885950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brachial artery access for transcatheter aortic valve implantation.","authors":"Robert Topalo,&nbsp;Petr Hájek,&nbsp;Karel Vik,&nbsp;Radka Adlová,&nbsp;Milan Horn,&nbsp;Josef Veselka","doi":"10.5114/aic.2021.104782","DOIUrl":"https://doi.org/10.5114/aic.2021.104782","url":null,"abstract":"We describe a case of an 80-year-old male patient with symptomatic severe aortic stenosis treated with transcatheter valve implantation (TAVI). The most common and preferred type of transcatheter valve delivery is through the femoral artery. However, if transfemoral access is not possible, an alternate route may be chosen. Such routes include, but are not limited to, direct aortic access, subclavian/axillary access, or transapical access, each one having their advantages and disadvantages [1, 2]. In our patient, transfemoral access was not possible due to extreme tortuosity of both pelvic arteries revealed on preoperative angiography. Computed tomography (CT) angiography was used to assess the diameter of the subclavian, axillary and brachial arteries (Figures 1 A, B). Duplex ultrasound verified the proximal diameter of the right brachial artery to be 6.7 mm (Figure 1 C). This diameter was sufficient to perform TAVI with an Evolut R 34 mm valve via the brachial artery. This approach offers multiple benefits, primarily, relatively easy access, avoidance of preparation of an artery in the otherwise very complex axillary and subclavian region, therefore decreasing chances of iatrogenic injury, and a quick recovery after the procedure. Other benefits of transbrachial delivery are usually minimal tortuosity of the arterial segment and minimal calcification. A major limitation of this approach is the diameter of the brachial artery. Other disadvantages are the same as for subclavian/axillary access and involve the angle of the aorta from the horizontal plane, as well as the unfavorable angle of valve delivery into the left ventricular outflow tract. Under full general anesthesia, a 45 cm long 5F sheath was introduced through the right femoral artery, and a temporary pacemaker via the right femoral vein. Surgical preparation of the right brachial artery was conducted (Figure 1 D). Anatomically, the brachial artery is a continuation of the axillary artery beyond the lower margin of the teres major muscle. After the arteriotomy of the brachial artery, a 18F sheath was introduced. Passage of the guidewire via the brachiocephalic artery was controlled by contralateral injection of contrast dye by a Vitek catheter (Cook, Bloomington, IN, USA). The CoreValve Evolut R 34 mm (Medtronic, Minneapolis, MN, USA) was delivered through the EnVeo R delivery catheter system. At the end of the procedure, the brachial artery was closed by arterial suture. Echocardiography performed after TAVI demonstrated only a trace of paravalvular regurgitation and a mean gradient of 11 mm Hg. One-year after implantation, echocardiographic findings were unchanged compared to pre-discharge findings. The patient was completely asymptomatic and doing well, maintaining a physically active lifestyle. There was no clinical evidence of any forearm dysfunction after the procedure or at the 1-year follow-up examination. As this was our first case of transbrachial access, the decision was made ","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"124-125"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/e2/PWKI-17-43651.PMC8039932.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38885952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of pre-hospital medication administration in ST-elevation myocardial infarction patients on left ventricular ejection fraction and intra-hospital death.","authors":"Magdalena Żurowska-Wolak,&nbsp;Michał Owsiak,&nbsp;Stanisław Bartuś,&nbsp;Marcin Mikos","doi":"10.5114/aic.2021.104766","DOIUrl":"https://doi.org/10.5114/aic.2021.104766","url":null,"abstract":"<p><strong>Introduction: </strong>Currently, invasive cardiology techniques are the preferred method of treatment for patients with ST-elevation myocardial infarction (STEMI). Improving the care of patients with STEMI is possible by minimizing the time that elapses from the onset of pain to the start of treatment. As studies indicate, early pharmacotherapy, especially with antiplatelet and anticoagulant medications, allows for their early effectiveness.</p><p><strong>Aim: </strong>To assess the influence of early administration of antiplatelet (clopidogrel) and anticoagulant medications in the pre-hospital period in patients with ST-elevated myocardial infarction on the frequency of in-hospital deaths and on the left ventricular ejection fraction evaluated at hospital discharge.</p><p><strong>Material and methods: </strong>In this study, a retrospective analysis of 573 patients hospitalized due to ST-segment elevation myocardial infarction in one of Krakow's hospitals from January 2011 to December 2015 (excluding the whole of 2013) was used as a research method.</p><p><strong>Results: </strong>As many as 97% of patients received pre-hospital pharmacotherapy, but only 46.0% of respondents received unfractionated heparin, and 19.2% received clopidogrel. The in-hospital mortality rate was 6.7%, but among patients prehospitally treated with clopidogrel and unfractionated heparin, the in-hospital mortality rate was 1.1%. Prehospital administration of clopidogrel significantly decreased the possibility of reduced left ventricular ejection fraction (OR = 0.27; 95% CI: 0.09-0.90).</p><p><strong>Conclusions: </strong>Among pre-hospital procedures, only administration of a second antiplatelet drug (clopidogrel) significantly decreased the risk of reduced left ventricular ejection fraction, and administration of clopidogrel or heparin, or a combination of both, significantly decreased the risk of in-hospital death in patients with STEMI.</p>","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"39-45"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/54/PWKI-17-43636.PMC8039926.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38884635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Staying connected during the COVID-19 pandemic: highlights from the Paediatric and Congenital Interventional Cardiology Early-Career Society (PICES) 2020 activities.","authors":"Sebastian Góreczny,&nbsp;Wendy Whiteside,&nbsp;Tacy Downing,&nbsp;Varun Aggarwal,&nbsp;Gurumurthy Hiremath,&nbsp;Ryan Callahan,&nbsp;Brian Boe","doi":"10.5114/aic.2021.104762","DOIUrl":"https://doi.org/10.5114/aic.2021.104762","url":null,"abstract":"The Paediatric and congenital Interventional Cardiology Early-Career Society (PICES) was conceived in a hallway conversation during the 2011 Society for Cardiovascular Angiography and Interventions (SCAI) meeting in Baltimore, MD and was subsequently formally established in July of 2011 [1] Since its inception, the organization has focused on promoting clinical education, fostering multicentre research collaboration, developing leadership skills, and promoting professional networking among the early-career (within 10 years of their training) paediatric/congenital interventional cardiologists as well as fellows-in-training Membership is available free of charge to anyone in congenital cardiology training, congenital interventional cardiology training, or an interventional cardiology faculty early within their career PICES is a special interest group of the SCAI, and multiple previous and current PICES executive committee members have served on the Congenital Heart Disease (CHD) council of the SCAI Currently the society consists of more than 200 members with approximately 60% United States and 40% international representation","PeriodicalId":520756,"journal":{"name":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","volume":" ","pages":"1-5"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/48/d7/PWKI-17-43632.PMC8039930.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38884631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}